Ghent University Academic Bibliography

Advanced

Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer

Wim Ceelen UGent, Yves Van Nieuwenhove UGent, Simon Van Belle UGent, Hannelore Denys UGent and Piet Pattyn UGent (2012) ANNALS OF SURGICAL ONCOLOGY. 19(7). p.2352-2359
abstract
Limited data are available on the use of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with recurrent stage III ovarian cancer. Patients with recurrent, heavily pretreated ovarian cancer were enrolled onto a phase II multimodal protocol consisting of extensive cytoreduction followed by HIPEC. Forty-two women were treated from October 2002 until January 2009. Chemoperfusion was performed with cisplatin in 59% and oxaliplatin in 41% of patients. A macroscopically complete resection was achieved in 50% of patients. No mortality occurred, and the major morbidity rate was 21%. After a mean follow-up of 21 months, median overall survival (OS) was 37 months (95% confidence interval 12.2-61.8) and median progression-free survival was 13 months (95% confidence interval 6.9-19.1). In univariate analysis, OS was influenced by completeness of cytoreduction, type of chemoperfusion drug, nodal status, and tumor grade. In a Cox regression model, only completeness of cytoreduction (hazard ratio 0.06-0.8, P = .022) and tumor grade (hazard ratio 1.23-12.6, P = .021) were independent predictors of OS. In selected patients with heavily pretreated recurrent ovarian cancer, cytoreduction combined with HIPEC may provide a meaningful OS with acceptable morbidity. Optimal results are achieved in patients with a macroscopically complete resection and biologically favorable disease.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
SURGERY-PERITONECTOMY, PERITONEAL CARCINOMATOSIS, ONCOLOGY-GROUP, CHEMOTHERAPY, OXALIPLATIN, TRIAL, CISPLATIN, CHEMOHYPERTHERMIA, COMBINATION, PACLITAXEL
journal title
ANNALS OF SURGICAL ONCOLOGY
Ann. Surg. Oncol.
volume
19
issue
7
pages
2352 - 2359
Web of Science type
Article
Web of Science id
000305558000038
JCR category
SURGERY
JCR impact factor
4.12 (2012)
JCR rank
8/195 (2012)
JCR quartile
1 (2012)
ISSN
1068-9265
DOI
10.1245/s10434-009-0878-6
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2048303
handle
http://hdl.handle.net/1854/LU-2048303
date created
2012-02-28 11:15:32
date last changed
2012-09-20 13:55:59
@article{2048303,
  abstract     = {Limited data are available on the use of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with recurrent stage III ovarian cancer. 
Patients with recurrent, heavily pretreated ovarian cancer were enrolled onto a phase II multimodal protocol consisting of extensive cytoreduction followed by HIPEC. 
Forty-two women were treated from October 2002 until January 2009. Chemoperfusion was performed with cisplatin in 59\% and oxaliplatin in 41\% of patients. A macroscopically complete resection was achieved in 50\% of patients. No mortality occurred, and the major morbidity rate was 21\%. After a mean follow-up of 21 months, median overall survival (OS) was 37 months (95\% confidence interval 12.2-61.8) and median progression-free survival was 13 months (95\% confidence interval 6.9-19.1). In univariate analysis, OS was influenced by completeness of cytoreduction, type of chemoperfusion drug, nodal status, and tumor grade. In a Cox regression model, only completeness of cytoreduction (hazard ratio 0.06-0.8, P = .022) and tumor grade (hazard ratio 1.23-12.6, P = .021) were independent predictors of OS. 
In selected patients with heavily pretreated recurrent ovarian cancer, cytoreduction combined with HIPEC may provide a meaningful OS with acceptable morbidity. Optimal results are achieved in patients with a macroscopically complete resection and biologically favorable disease.},
  author       = {Ceelen, Wim and Van Nieuwenhove, Yves and Van Belle, Simon and Denys, Hannelore and Pattyn, Piet},
  issn         = {1068-9265},
  journal      = {ANNALS OF SURGICAL ONCOLOGY},
  keyword      = {SURGERY-PERITONECTOMY,PERITONEAL CARCINOMATOSIS,ONCOLOGY-GROUP,CHEMOTHERAPY,OXALIPLATIN,TRIAL,CISPLATIN,CHEMOHYPERTHERMIA,COMBINATION,PACLITAXEL},
  language     = {eng},
  number       = {7},
  pages        = {2352--2359},
  title        = {Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer},
  url          = {http://dx.doi.org/10.1245/s10434-009-0878-6},
  volume       = {19},
  year         = {2012},
}

Chicago
Ceelen, Wim, Yves Van Nieuwenhove, Simon Van Belle, Hannelore Denys, and Piet Pattyn. 2012. “Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer.” Annals of Surgical Oncology 19 (7): 2352–2359.
APA
Ceelen, Wim, Van Nieuwenhove, Y., Van Belle, S., Denys, H., & Pattyn, P. (2012). Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2352–2359.
Vancouver
1.
Ceelen W, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. ANNALS OF SURGICAL ONCOLOGY. 2012;19(7):2352–9.
MLA
Ceelen, Wim, Yves Van Nieuwenhove, Simon Van Belle, et al. “Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer.” ANNALS OF SURGICAL ONCOLOGY 19.7 (2012): 2352–2359. Print.